BackgroundImmune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identifie
Data shown are median values (interquartile range) unless otherwise indicated. * At time of sampling § HLA-B*27, B51, B*5701/03, B*5801 and B*8101 Characteristics of HVTN 502 and 503 trial participant
Burk Lab HPV DNA data Study Description A Phase II, open-label, multi-center study that evaluated the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in
This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme
